43 results
8-K
EX-10.1
RNLX
Renalytix Plc
12 Jun 24
Departure of Directors or Certain Officers
5:00pm
not relate to the business efforts or research and development efforts in which, during the term of this Agreement, the Company actually is engaged
424B5
RNLX
Renalytix Plc
15 May 24
Prospectus supplement for primary offering
10:09am
, expanded research and development activities and costs associated with operating a public company.
Our expected use of the net proceeds from … factors, including the results of our research and development efforts, the timing of regulatory submissions, our ability to obtain additional financing
8-K
EX-99.1
RNLX
Renalytix Plc
15 May 24
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
7:00am
the year ago period.
Within operating expenses, research and development expenses were $2.2 million for the three months ended March 31, 2024 … ,
(in thousands, except share data)
Revenue
Cost of revenue
Gross profit (loss)
Operating expenses:
Research and development
General and administrative
424B5
RNLX
Renalytix Plc
9 Apr 24
Prospectus supplement for primary offering
4:31pm
, including conducting verification studies, commercialization efforts, expanded research and development activities and costs associated with operating … from this offering. The amounts and timing of our expenditures will depend upon numerous factors, including the results of our research and development
8-K
EX-99.1
5ko 38poih
15 Feb 24
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
7:00am
8-K
EX-99.1
hg51wqge5d
14 Nov 23
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
12:00am
10-Q
7lm2qqjgdp
14 Nov 23
Quarterly report
12:00am
8-K
EX-99.1
13k4aje0
28 Sep 23
Renalytix Reports Full Year Fiscal 2023 Results
7:31am
POS AM
o302 15u7xkqy
28 Sep 23
Prospectus update (post-effective amendment)
6:55am
POS AM
y53fdk
28 Sep 23
Prospectus update (post-effective amendment)
6:54am
10-K
0zyfsc bm3tlfq
28 Sep 23
Annual report
6:18am
6-K
a4lljdkgxb zg8wam
9 Jun 23
Current report (foreign)
7:01am
424B3
l9s9pzchsim16s56jh
10 May 23
Prospectus supplement
4:14pm
F-3
1f6or9is 6u0sdzb3l
2 May 23
Shelf registration (foreign)
4:40pm
6-K
gklrtd 0hx8z5dumj5
30 Mar 23
Current report (foreign)
7:01am
6-K
g3syxykd4d03z33
30 Nov 22
Current report (foreign)
7:31am
6-K
EX-99.3
8w6k3 8m8ik8phuodxl
22 Nov 22
Annual Report and For the Year Ended 30 June 2022
5:09pm
6-K
EX-99.1
9td1x7o
22 Nov 22
Annual Report and For the Year Ended 30 June 2022
5:09pm